CEL-SCI (FRA:LSR) Net Interest Income: €-0.38 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSR CEL-SCI Corp FRA:LSR
30 GF Score
Price €1.31
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Net Interest Income?

CEL-SCI FRA:LSR +1.55% 30 Net Interest Income is €-0.38 Mil as of Jun. 2026. GuruFocus rates FRA:LSR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. CEL-SCI's net interest income for the three months ended in Jun. 2026 was €-0.10 Mil. Its net interest income for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.38 Mil.

CEL-SCI Net Interest Income Related Terms

CEL-SCI Net Interest Income Historical Data

* Premium members only.

The historical data trend for CEL-SCI's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CEL-SCI Net Interest Income Chart

CEL-SCI Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.98 -1.09 -0.63 -0.67 -0.55

CEL-SCI Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.11 -0.08 -0.10 -0.10
FRA:LSR
30GF Score
CEL-SCI Corp FRA:LSR
Net Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Interest Income →
What does a Net Interest Income of €-0.38 Mil mean?
CEL-SCI (FRA:LSR) has a Net Interest Income of €-0.38 Mil as of Jun. 2026.
Is CEL-SCI's Net Interest Income too high?
CEL-SCI's current Net Interest Income is €-0.38 Mil. Overall, CEL-SCI has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Net Interest Income compare to HOWL and ZIVO?
CEL-SCI's Net Interest Income of €-0.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Interest Income for a Biotechnology company?
A good Net Interest Income depends on the Biotechnology industry context. However, Net Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Interest Income mean?
A high Net Interest Income can signal that a stock is expensive relative to its fundamentals. CEL-SCI's current Net Interest Income is €-0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Net Interest Income of €-0.38 Mil. The current Net Interest Income is €-0.38 Mil. CEL-SCI's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Interest Income calculated?
Net Interest Income is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Net Interest Income is €-0.38 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
30GF Score

Get the complete analysis for FRA:LSR

Net Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.31
Price